Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Characterizing heterogeneous cellular responses to perturbations.

Slack MD, Martinez ED, Wu LF, Altschuler SJ.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19306-11. doi: 10.1073/pnas.0807038105. Epub 2008 Dec 3.

2.

Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities.

Singh DK, Ku CJ, Wichaidit C, Steininger RJ 3rd, Wu LF, Altschuler SJ.

Mol Syst Biol. 2010 May 11;6:369. doi: 10.1038/msb.2010.22.

3.

Intratumor heterogeneity alters most effective drugs in designed combinations.

Zhao B, Hemann MT, Lauffenburger DA.

Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10773-8. doi: 10.1073/pnas.1323934111. Epub 2014 Jul 7.

4.

Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.

El-Awady RA, Hersi F, Al-Tunaiji H, Saleh EM, Abdel-Wahab AH, Al Homssi A, Suhail M, El-Serafi A, Al-Tel T.

Cancer Biol Ther. 2015;16(7):1056-70. doi: 10.1080/15384047.2015.1046023.

5.

A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer.

Lyons JM 3rd, Anthony CT, Thomson JL, Woltering EA.

Ann Surg Oncol. 2008 Dec;15(12):3407-14. doi: 10.1245/s10434-008-0145-2. Epub 2008 Sep 16.

PMID:
18795370
6.

Trait variability of cancer cells quantified by high-content automated microscopy of single cells.

Quaranta V, Tyson DR, Garbett SP, Weidow B, Harris MP, Georgescu W.

Methods Enzymol. 2009;467:23-57. doi: 10.1016/S0076-6879(09)67002-6.

7.

Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells.

Friesen C, Herr I, Krammer PH, Debatin KM.

Nat Med. 1996 May;2(5):574-7.

PMID:
8616718
8.

Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.

Viale M, Pastrone I, Pellecchia C, Vannozzi MO, Cafaggi S, Esposito M.

Anticancer Drugs. 1998 Jun;9(5):457-63.

PMID:
9660544
9.

Regulation of drug sensitivity by ribosomal protein S3a.

Hu ZB, Minden MD, McCulloch EA, Stahl J.

Blood. 2000 Feb 1;95(3):1047-55. Erratum in: Blood 2000 Sep 1;96(5):1632.

11.

[Anticancer drugs and pharmacologic actions].

Ogawa M.

Nihon Rinsho. 1997 May;55(5):1017-23. Review. Japanese.

PMID:
9155146
12.

Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel.

Miglietta A, Cavalli R, Bocca C, Gabriel L, Gasco MR.

Int J Pharm. 2000 Dec 4;210(1-2):61-7.

PMID:
11163988
13.

High dose of dexamethasone upregulates TCR/CD3-induced calcium response independent of TCR zeta chain expression in human T lymphocytes.

Nambiar MP, Enyedy EJ, Fisher CU, Warke VG, Tsokos GC.

J Cell Biochem. 2001 Aug 21-Sep 5;83(3):401-13.

PMID:
11596109
14.
15.

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.

Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D.

Oncogene. 1999 Apr 1;18(13):2241-51.

16.

Navigating the challenge of tumor heterogeneity in cancer therapy.

Fedele C, Tothill RW, McArthur GA.

Cancer Discov. 2014 Feb;4(2):146-8. doi: 10.1158/2159-8290.CD-13-1042.

17.

Intratumor heterogeneity: seeing the wood for the trees.

Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C.

Sci Transl Med. 2012 Mar 28;4(127):127ps10. doi: 10.1126/scitranslmed.3003854.

PMID:
22461637
18.

Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line.

Hochhauser D, Schnieders B, Ercikan-Abali E, Gorlick R, Muise-Helmericks R, Li WW, Fan J, Banerjee D, Bertino JR.

J Natl Cancer Inst. 1996 Sep 18;88(18):1269-75.

PMID:
8797766
19.
20.

Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.

Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP.

Mol Cancer Ther. 2007 Mar;6(3):1089-98.

Supplemental Content

Support Center